High-level erythroid lineage-directed gene expression using globin gene regulatory elements after lentiviral vector-mediated gene transfer into primitive human and …

H Hanawa, DA Persons, AW Nienhuis - Human gene therapy, 2002 - liebertpub.com
H Hanawa, DA Persons, AW Nienhuis
Human gene therapy, 2002liebertpub.com
Lentiviral vectors efficiently transduce primitive human hematopoietic cells and are capable
of transferring complex genomes. Vectors were designed with hypersensitive sites
containing regulatory elements from the β-globin locus control region linked to the β-globin
gene promoter to drive expression of the enhanced green fluorescent protein marker to
facilitate analysis of the pattern of gene expression in various hematopoietic lineages. Such
vectors gave higher level, induced expression in mouse erythroleukemia cells than a …
Lentiviral vectors efficiently transduce primitive human hematopoietic cells and are capable of transferring complex genomes. Vectors were designed with hypersensitive sites containing regulatory elements from the β-globin locus control region linked to the β-globin gene promoter to drive expression of the enhanced green fluorescent protein marker to facilitate analysis of the pattern of gene expression in various hematopoietic lineages. Such vectors gave higher level, induced expression in mouse erythroleukemia cells than a previously described vector that utilized an enhancer from the α locus and the ankyrin-1 promoter [Moreau-Gaudry, F., Xia, P., Jiang, G., Perelman, N.P., Bauer, G., Ellis, J., Surinya, K.H., Mavilio, F., Shen, C.K., and Malik, P. (2001). Blood 98, 2664-2672]. The addition of γ-globin intron sequences further augmented vector expression. Expression was also effectively targeted to the erythroid lineage in cultured human cells from peripheral blood and in mouse red blood cells in vivo, although lower levels of expression were also observed in other lineages. Thus, these newly described vectors provide a means to achieve high-level gene expression, predominantly in erythroid cells, an outcome that may have potential therapeutic application.
Mary Ann Liebert